Register now for FREE unlimited access to Reuters.com
MILAN, June 8 (Reuters) – Shares in Credit Suisse (CSGN.S) turned sharply higher on Wednesday afternoon, with traders citing an Inside Paradeplatz report that U.S-based State Street (STT.N) is planning a takeover bid for the troubled lender, though some in the industry doubt the claim.
Credit Suisse shares ended up 3.8% in Zurich after jumping following the report in the Swiss financial blog. From lows hit earlier in the day, the shares were up more than 14%. The broader European stock market (.STOXX) was down 0.7%.
The stock had dropped close to its lowest in over 20 years earlier in the session after the company warned of a likely second-quarter loss as volatility hit its investment bank. read more
In the U.S., shares of State Street (STT.N)finished down 5.4% at $69.04. U.S.-listed shares of Credit Suisse closed down 1% at $6.87.
Citing one unidentified source, Inside Paradeplatz said State Street would bid 9 Swiss francs a share, a premium of more than 30% to Tuesday’s closing price. That would value Credit Suisse at 23 billion francs ($23.6 billion).
“We are not going to respond to an earlier news report,” State Street said in a statement. “As we have previously discussed, we are focused on our pending acquisition of Brown Brothers Harriman’s Investors Services business.”
Credit Suisse declined to comment.
Analysts were sceptical.
“I’d struggle to see why State Street would be the buyer of a global full service investment bank franchise,” said Michael Brown, analyst at Keefe, Bruyette & Woods. “It extends beyond their core competency as an asset servicing and asset management firm.”
State Street announced last September that it had agreed to buy investment bank Brown Brothers Harriman & Co’s investor services business for $3.5 billion in cash, strengthening its hand in the battle to be the world’s biggest custodian bank. read more
Jefferies analysts wrote that they saw the combination as “highly unlikely” citing State Street’s pending deal to buy Brown Brothers Harriman’s investor services business and the Swiss bank’s legal and business challenges.
A top U.S. brokerage, in a message to clients, questioned the rationale of any State Street interest for the Swiss bank, citing unclear synergies for the U.S. custodian, along with the risk of capital costs, job cuts and litigation risks.
The deal speculation comes as Credit Suisse on Wednesday delivered a third consecutive quarterly profit warning.
The bank has described 2022 as a “transition” year in which it is trying to turn the page on costly scandals that brought a near total reshuffle of top management and a restructuring seeking to curtail risk-taking, particularly in its investment bank.
Shares have lost nearly half their value since two of the biggest shocks, the collapse of $10 billion in supply-chain finance funds linked to Greensill Capital and a more than $5 billion loss on the unwinding of trades by investment firm Archegos, hit the bank in March 2021. read more
Those blows prompted questions over whether the flagship Swiss lender, left vulnerable by scandals, could be challenged by investors demanding its break-up, or that its shrinking stock-market value makes it a target for a foreign hostile takeover. read more
Top-ten shareholder Artisan Partners told Reuters last month that Credit Suisse should start looking for a new CEO, the first major investor to publicly call for such a move. read more
Separately, sources told Reuters last week that Credit Suisse is in the early stages of weighing options to bolster its capital after a string of losses eroded its financial buffers. read more
($1 = 0.9739 Swiss francs)
Reporting by Danilo Masoni; Additional reporting by Sinead Carew, Brenna Hughes Neghaiwi and Niket Nishant; Editing by Ira Iosebashvili, Elaine Hardcastle and Richard Chang
Our Standards: The Thomson Reuters Trust Principles.
Written by: smartinvestorradio
Vaccines are by far the most powerful tool available against the coronavirus, protecting people from getting seriously ill, being hospitalized, and dying from the virus. Unlike many less developed countries, the US has enough doses to vaccinate everyone as well as the necessary infrastructure to support the rollout. The problem: not everyone wants the shot. "We do have a problem with vaccine uptake that is very serious in the United […]
Information presented is for entertainment and general information purposes only. Opinions expressed are those of the presenter only. We make no promises or guarantees of investment performance. None of the information presented here is intended to form the basis for any offer or recommendation or have any regard to investment objectives to the needs of any specific person. Smart Investor Radio is not a broker-dealer, certified financial planner or registered investment adviser.